Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

  title={Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.},
  author={I. Jacobson and S. Gordon and Kris V. Kowdley and E. Yoshida and M. Rodrigueztorres and M. Sulkowski and M. Shiffman and E. Lawitz and G. Everson and M. Bennett and E. Schiff and M. T. Al-Assi and G. M. Subramanian and D. An and M. Lin and J. McNally and D. Brainard and William T. Symonds and J. McHutchison and Keyur Patel and J. Feld and S. Pianko and D. Nelson},
  journal={The New England journal of medicine},
  volume={368 20},
  • I. Jacobson, S. Gordon, +20 authors D. Nelson
  • Published 2013
  • Medicine
  • The New England journal of medicine
  • BACKGROUND Patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3 for whom treatment with peginterferon is not an option, or who have not had a response to prior interferon treatment, currently have no approved treatment options. In phase 2 trials, regimens including the oral nucleotide polymerase inhibitor sofosbuvir have shown efficacy in patients with HCV genotype 2 or 3 infection. METHODS We conducted two randomized, phase 3 studies involving patients with chronic HCV… CONTINUE READING

    Paper Mentions

    The present study evaluates neurocognitive performance as well as measures of mood, quality of life, and fatigue in patients with chronic hepatitis C infection. In a prospective… Expand
    ConditionsHepatitis C, Chronic
    Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
    • 742
    • Open Access
    Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
    • 1,451
    • Open Access
    EASL Recommendations on Treatment of Hepatitis C 2018.
    • 1,386
    • Highly Influenced
    • Open Access
    Global Distribution and Prevalence of Hepatitis C Virus Genotypes
    • 1,106
    • Open Access


    Publications referenced by this paper.
    Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    • 6,407
    • Open Access
    Sofosbuvir for previously untreated chronic hepatitis C infection.
    • 1,623
    • Open Access
    Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.
    • 596
    • Open Access
    • 1971
    • 25,247